EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Guideline for pharmacological treatment of schizophrenia 2022

Japanese Society of Neuropsychopharmacology, Japanese Society of Clinical Neuropsychopharmacology

Neuropsychopharmacology Reports · 2025-03 · 45 (1)

DOI: 10.1002/npr2.12497 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 25.11.2024. Verfasst von Japanese Society of Neuropsychopharmacology und 1 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 449 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Japanese Society of Neuropsychopharmacology, & Japanese Society of Clinical Neuropsychopharmacology (2025). Guideline for pharmacological treatment of schizophrenia 2022. Neuropsychopharmacology Reports, 45(1). https://doi.org/10.1002/npr2.12497

Vancouver

Japanese Society of Neuropsychopharmacology, Japanese Society of Clinical Neuropsychopharmacology. Guideline for pharmacological treatment of schizophrenia 2022. Neuropsychopharmacology Reports. 2025;45(1). doi:10.1002/npr2.12497

BibTeX
@article{JapaneseSocietyofNeuropsychopharmacology2025,
  author = {Japanese Society of Neuropsychopharmacology, Japanese Society of Neuropsychopharmacology and Japanese Society of Clinical Neuropsychopharmacology, Japanese Society of Clinical Neuropsychopharmacology},
  title = {Guideline for pharmacological treatment of schizophrenia 2022},
  journal = {Neuropsychopharmacology Reports},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1002/npr2.12497}
}
Kostenlos starten →